
NRX Pharmaceuticals (NRXP) Stock Forecast & Price Target
NRX Pharmaceuticals (NRXP) Analyst Ratings
Bulls say
NRX Pharmaceuticals is positioned favorably because it has already transitioned from a clinical story to a commercial one with KETAFREE approved ahead of schedule, a 17-person sales force covering 80% of the ketamine market, and launch stock of about 5 million units with capacity for 1 million units per month. Its pipeline also looks de-risked by existing clinical data: NRX-100 and NRX-101 are based on known molecules, while NRX-101 has shown a greater-than-two-fold response improvement and an eight-fold remission increase versus TMS alone, with 87% response and 72% remission at six weeks in real-world data. The opportunity is amplified by large, underserved markets and near-term catalysts, including a $400M U.S. ketamine market, an $11.2M DARPA contract, and potential 2026/2027 FDA actions for NRX-100 and NRX-101 in bipolar depression with suicidality.
Bears say
NRX Pharmaceuticals is a clinical-stage company whose Q2 2026 results underscored weak commercial traction, with revenue of only $1.1 million versus estimates of $3.0–16.6 million and no company guidance to anchor expectations. The business also posted a wide net loss of $16.5 million, or $(0.44) per share, highlighting continued heavy cash burn and a development model that remains dependent on uncertain future clinical and regulatory progress rather than durable sales. Although the HOPE business began generating revenue in Q3 2025, the scale remains too small to offset the company’s losses, leaving the stock exposed to financing risk and execution uncertainty.
This aggregate rating is based on analysts' research of NRX Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
NRX Pharmaceuticals (NRXP) Analyst Forecast & Price Prediction
Start investing in NRX Pharmaceuticals (NRXP)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About NRX Pharmaceuticals (NRXP) Forecast
NRX Pharmaceuticals (NRXP) Analyst Forecast & Price Prediction
Start investing in NRX Pharmaceuticals (NRXP)
Order type
Buy in
Order amount
Est. shares
0 shares